Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Nov 04, 2025
|
Prelude Therapeutics Secures $60 Million Incyte Deal, Pauses SMARCA2 Program to Focus on JAK2V617F and KAT6A Degraders
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$232.61M |
$1.40
-2.45%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Enanta is actively developing antiviral small-molecule therapeutics targeting RSV, fitting the Antiviral Small-Molecule Therapeutics theme.
|
$231.29M |
$11.12
+2.77%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$229.71M |
$52.00
+1.05%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
ZURA
Zura Bio Limited
Zura Bio develops immunology therapeutics for autoimmune and inflammatory diseases (Immunology Therapeutics).
|
$227.70M |
$3.54
-3.67%
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$226.43M |
$3.13
-3.10%
|
|
CRBU
Caribou Biosciences, Inc.
Company is developing gene-editing gene therapy platforms (CRISPR-based chRDNA) for therapeutic applications.
|
$226.00M |
$2.25
-7.61%
|
|
AARD
Aardvark Therapeutics, Inc. Common Stock
ARD-101 and ARD-201 are oral small-molecule therapeutics targeting satiety pathways for metabolic and rare-disease indications.
|
$225.42M |
$10.13
-2.45%
|
|
PRLD
Prelude Therapeutics Incorporated
Prelude is a clinical-stage biotech focused on oncology, with an advanced pipeline targeting SMARCA2/SMARCA4 and related cancer pathways.
|
$224.71M |
$1.64
-58.79%
|
|
BDTX
Black Diamond Therapeutics, Inc.
BDTX operates as a biotechnology company focused on oncology therapeutics, i.e., Biotech - Oncology.
|
$224.61M |
$3.71
-5.95%
|
|
FENC
Fennec Pharmaceuticals Inc.
Direct product in oncology/supportive care with FDA-approved PEDMARK therapy for cisplatin-induced ototoxicity.
|
$224.54M |
$8.15
+0.25%
|
|
PRQR
ProQR Therapeutics N.V.
ProQR's Axiomer platform uses oligonucleotide-based RNA editing (EONs) to direct ADAR-mediated editing.
|
$218.20M |
$2.42
-6.56%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$216.94M |
$5.75
-5.50%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$215.16M |
$4.02
-1.95%
|
|
XGN
Exagen Inc.
Exagen's biomarker-based tests (e.g., AVISE CTD, SLE T-cell markers, RA33) align with companion diagnostics.
|
$212.97M |
$11.13
-5.87%
|
|
RNAC
Cartesian Therapeutics, Inc.
Lead platform is an autologous cell therapy using mRNA CAR-T, a direct cell-therapy product line.
|
$211.01M |
$7.80
-4.06%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CRGX's core offerings are oncology CAR-T therapies (firi-cel, CRG-23), placing it in Biotech - Oncology.
|
$206.13M |
$4.47
|
|
QTRX
Quanterix Corporation
Offers contract research services via its Accelerator Lab, aligning with CRO-type activities.
|
$205.41M |
$5.24
-1.04%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$198.48M |
$8.84
+3.76%
|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$197.54M |
$4.68
-8.59%
|
|
NTHI
Neonc Technologies Holdings, Inc.
Directly produces oncology-focused biotech therapies; lead programs NEO100/NEO212 targeting brain cancers.
|
$193.88M |
$10.45
+2.55%
|
|
GNFT
Genfit S.A.
GENFIT's ELAFIBRONOR in Primary Biliary Cholangitis (PBC) represents a core liver-disease therapeutic offering.
|
$193.14M |
$3.89
+0.52%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$193.14M |
$1.45
-9.94%
|
|
CATX
Perspective Therapeutics, Inc.
Company directly develops and provides radiopharmaceuticals using alpha-emitting Lead-212 for targeted cancer therapy and diagnostic imaging via 203Pb in a theranostic approach.
|
$192.99M |
$2.36
-9.23%
|
|
MDWD
MediWound Ltd.
MediWound's core products are enzymatic proteins/enzymes (NexoBrid, EscharEx) used for wound debridement, aligning with Recombinant Proteins & Enzymes.
|
$192.57M |
$17.76
-3.06%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$191.74M |
$1.81
-2.69%
|
|
PLX
Protalix BioTherapeutics, Inc.
Protalix manufactures recombinant proteins/enzymes (e.g., Elelyso, Elfabrio) using its plant-based ProCellEx system.
|
$190.26M |
$2.35
-1.88%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$187.23M |
$2.17
-4.20%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$185.49M |
$1.55
-2.81%
|
|
OABI
OmniAb, Inc.
OmniAb's core offering is the Antibody Discovery Platform enabling rapid generation of human antibodies through engineered transgenic animals and associated discovery tools.
|
$181.06M |
$1.49
+0.34%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$180.50M |
$16.26
-2.46%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$180.03M |
$1.11
-5.93%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$178.60M |
$1.68
-6.15%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$178.22M |
$4.73
+0.42%
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$177.24M |
$4.83
-5.38%
|
|
CCCC
C4 Therapeutics, Inc.
Lead assets (e.g., cemsidomide) are orally bioavailable small-molecule degraders, fitting the 'Oral Small Molecule Therapeutics' category.
|
$176.10M |
$2.29
-7.86%
|
|
IMDX
Insight Molecular Diagnostics Inc.
GraftAssureDx functions as a biomarker-based diagnostic that could be viewed as a Companion Diagnostics offering.
|
$175.03M |
$6.11
-0.25%
|
Showing page 14 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
